Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
341-360 of 2,120 trials

Urothelial Cancer: BT8009 Treatment Study

We are investigating whether the new drug BT8009, alone or with pembrolizumab, can help patients with advanced urothelial cancer live longer and respond better than standard chemotherapy.

Locally Advanced or Metastatic Urothelial Cancer>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncologyUrology

Neuroblastoma: ABTL0812 Treatment for Children

We are testing a new drug, ABTL0812, in children with relapsed or refractory neuroblastoma and other solid tumors. The study aims to find the best dose and evaluate its safety and effectiveness when used alone or with other therapies.

Relapsed/Refractory Neuroblastoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncologyPediatrics

Small Cell Lung Cancer: BI 764532 Treatment Study

We are testing different doses of BI 764532 in patients with relapsed small cell lung cancer and other neuroendocrine cancers. The goal is to see if this treatment can help improve outcomes for those who have not responded to prior therapies.

Small Cell Lung CancerNeuroendocrine CarcinomaLarge Cell Neuroendocrine Carcinoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Advanced Solid Tumors: [68Ga]Ga-DPI-4452 and [177Lu]Lu-DPI-4452 Study

We are studying the safety and effectiveness of two new treatments for patients with advanced solid tumors that cannot be removed by surgery. This trial also looks at how well these treatments can help in imaging the tumors.

Colorectal CancerDuctal Adenocarcinoma of PancreasClear Cell Renal Cell Carcinoma6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Cancer Treatment Continuation Study

We are offering ongoing treatment for cancer patients who participated in earlier studies. This study checks the safety of the therapy while ensuring patients have access to their treatment.

Cancer Treatment Continuation>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Glofitamab for Pediatric B-Cell Non-Hodgkin Lymphoma

We are studying the safety and effectiveness of glofitamab alone and with other treatments for children and young adults with relapsed or refractory B-cell non-Hodgkin lymphoma. This research aims to find better options for managing this challenging cancer.

B-cell Non-Hodgkin's Lymphoma6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Multiple Myeloma: Elranatamab Treatment Study

We are studying the effectiveness of Elranatamab for patients with relapsed or refractory multiple myeloma who have already been treated with three different drug classes. This trial aims to see if it can help achieve better disease control.

Multiple Myeloma>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Pleural Mesothelioma: New Chemotherapy and Immunotherapy Study

We are exploring a new treatment combining chemotherapy and immunotherapy for patients with inoperable pleural mesothelioma. The study will evaluate treatment completion rates, side effects, and overall quality of life.

Inoperable Pleural Mesothelioma1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Fetal and Neonatal Alloimmune Thrombocytopenia: Nipocalimab Study

We are testing nipocalimab in pregnant individuals at risk of FNAIT to see if it can lower the chances of severe complications for the baby. This study compares the treatment to a placebo to evaluate its effectiveness.

Neonatal Alloimmune Thrombocytopenia>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsInfectious Diseases

Advanced Non-Small Cell Lung Cancer: Zongertinib Study

We are testing whether zongertinib (BI 1810631) can improve outcomes for patients with advanced non-small cell lung cancer with HER2 mutations compared to standard treatment options.

Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Lower Respiratory Infections: Acyclovir Therapy

We are studying whether acyclovir can help ventilated patients with lower respiratory infections and herpes simplex virus. The trial aims to see if it improves survival and reduces hospital stays.

Pneumonia with Herpes Simplex Virus Infection6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesInfectious DiseasesPulmonology

HER2-Positive Breast Cancer: GLSI-100 Treatment Study

We are testing a new peptide treatment for patients with HER2-positive breast cancer at high risk of recurrence after standard therapies. The study aims to see if it improves outcomes compared to a placebo.

Breast CancerHER2 Positive Breast Cancer>2 yearsConfirmation phase (III)Investigational MedicinesCost ReimbursementPartially RemoteOncology

Dupilumab for Young Children with Uncontrolled Asthma

We are studying whether dupilumab can help reduce severe asthma attacks in children aged 2 to under 6 years. The trial will also evaluate the safety and tolerability of this treatment.

Asthma and Wheezing1-2 yearsConfirmation phase (III)Standard MedicinesPartially RemoteAllergologyPediatricsPulmonology

Pulmonary Arterial Hypertension: Triple Therapy Study

We are investigating whether a new combination of treatments, including an injectable medication, improves health outcomes for patients with pulmonary arterial hypertension. This study compares it to a standard oral treatment to see which is more effective.

Pulmonary Arterial Hypertension6-12 monthsConfirmation phase (III)Monitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Multiple Sclerosis: Frexalimab vs. Teriflunomide

We are studying a new medication, frexalimab, for adults with relapsing forms of multiple sclerosis. The goal is to see if it works better than teriflunomide in reducing relapses and improving quality of life.

Multiple Sclerosis>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Frexalimab for Nonrelapsing Secondary Progressive Multiple Sclerosis

We are studying whether frexalimab can help delay disability progression in adults with nonrelapsing secondary progressive multiple sclerosis. The trial also examines its effects on quality of life and safety.

Multiple Sclerosis>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Cervical Cancer: Volrustomig Treatment Study

We are studying whether volrustomig is safe and effective for women and young adults with high-risk locally advanced cervical cancer after initial treatment. This trial compares volrustomig to a placebo to see if it improves health outcomes.

Locally Advanced Cervical CancerConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesPartially RemoteOncology

Chronic Hepatitis D: Bulevirtide Treatment Study

We are studying the effects of Bulevirtide in patients with chronic hepatitis D to see how well it reduces the virus and improves liver health. This research will help us understand the treatment's safety and effectiveness over time.

Hepatitis DConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesHepatologyInfectious Diseases

Secukinumab: Long-Term Safety Study

We are evaluating the long-term safety of Secukinumab for patients who have previously participated in a related study. This trial will help us understand any potential side effects of continued treatment.

Psoriatic ArthritisAnkylosing SpondylitisNon-radiographic Axial Spondyloarthritis>2 yearsMonitoring phase (IV)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteDermatologyInternal MedicineRheumatology

Muscle Invasive Bladder Cancer: New Treatment Combination

We are studying a combination of three medications for patients with muscle invasive bladder cancer who cannot take cisplatin. The goal is to see if this approach can effectively shrink tumors before surgery.

Bladder CancerEfficacy phase (II)No PlaceboInvestigational MedicinesInternal MedicineOncologyUrology